Of several aspects discussed in this paper on real‐world outcomes of CBF‐AML, one thing stands out: the benefit of adding KIT inhibitors (dasatinib or midostaruin) to intensive chemotherapy in CBF‐AML. This evidence concerns the gene CEBPZ and acute myeloid leukemia.